exRNAdisease

General Information

Database ID:

exR0088005

RNA Name:

hsa-miR-302b-3p

RNA Type:

miRNA

Chromosome:

chr4

Starnd:

Coordinate:

Start Site(bp):

112648489

End Site(bp):

112648511

External Links:

Disease Information

Disease Name:	Breast Cancer
Disease Category:	Cancers
MeSH ID:	D001943
Type:	Neoplasms/Breast Neoplasms
Alias:	Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID:	GSE101841
Description:	Serum microRNA profile of Her2 positive metastatic breast cancer patients
Experimental Design:	Trastuzumab therapy
Case Disease Type:	Breast Cancer
Case Disease SubType:	HER2 positive metastatic breast cancer
Case Sample:	Breast Cancer Trastuzumab resistant
Control Sample:	Trastuzumab sensitive
Number of Case:	42
Number of Control:	61
Number of Samples:	103

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
RPP14	chr3	58306247	58324695	+
SWSAP1	chr19	11374666	11376951	+
GPBP1	chr5	57173948	57264679	+
C18orf21	chr18	35972625	35979286	+
PXYLP1	chr3	141228726	141367753	+
ALG5	chr13	36949738	37000261	-
SERINC1	chr6	122443351	122471807	-
RGMA	chr15	93035273	93089204	-
CLCN6	chr1	11806096	11848079	+
KCTD10	chr12	109448655	109477359	-
PLS3	chrX	115561174	115650861	+
RPLP1	chr15	69452814	69456205	+
DNAJB6	chr7	157335381	157417439	+
SYAP1	chrX	16719612	16765340	+
RNF149	chr2	101271219	101308701	-
SLC35G1	chr10	93893973	93956062	+
MSL1	chr17	40121971	40136917	+
SND1	chr7	127652194	128092609	+
WASF3	chr13	26557683	26688948	+
CTR9	chr11	10751246	10801625	+
HMGCS1	chr5	43287470	43313512	-
CDK6	chr7	92604921	92836594	-
WDR37	chr10	1049538	1132384	+
ATP6V1B2	chr8	20197381	20226819	+
CTSC	chr11	88293592	88337761	-
HSPA9	chr5	138553756	138575416	-
ZNF281	chr1	200404940	200410056	-
CELF2	chr10	10798397	11336675	+
TNRC6A	chr16	24610209	24827632	+
ATP13A2	chr1	16985958	17011928	-

miRNA targets:

circRNA targets:

circRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa_circ_0000943	chr19	47421744	47440665	+

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC011503.2	chr19	23927788	23929287	+
AC021078.1	chr5	149494314	149504670	-
AC125257.1	chr17	41848518	41851447	-
AL049840.4	chr14	103694516	103695050	-
ARHGAP27P1-BPTFP1-KPNA2P3	chr17	64749663	64781707	-
FGD5-AS1	chr3	14920347	14948424	-
MIR17HG	chr13	91347820	91354579	+
NEAT1	chr11	65422774	65445540	+
NORAD	chr20	36045618	36051018	-
SNHG16	chr17	76557764	76565348	+
XIST	chrX	73820649	73852723	-

Display:

Experiment Detail

GEO ID:	GSE101841
Sample Source:	Blood
Source Fraction:	Serum
Platform:	GPL23138
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	1808
Sample treatment protocol:	NA
RNA Extract protocol:	Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions.
RNA library preparation protocol:	Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID:	29691399
Title:	A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Author:	Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E
Journal:	Nat Commun. 2018 Apr 24;9(1):1614.
Description:	MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.